Gapping up
In reaction to earnings/guidance:
- CLF +3.7%, BCOR +1.8%
Other news:
- CLSD +53.3% (positive safety results from cohort 1 of OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) for the treatment of Wet AMD)
- FUSN +12.7% (announces preliminary data from FPI-1434 Phase 1 study)
- AMPE +11.7% (received regulatory approval to expand enrollment of its AP-019 Phase II study to India. The study will utilize inhaled Ampion™ to treat those suffering from respiratory distress due to COVID-19)
- RAPT +9.1% (extends momentum from +116% move on Monday; also commences $125 mln stock offering)
- NRXP +8.9% (data from its ZYESAMI Expanded Access Protocol)
- OTIC +6.4% (initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty)
- DPW +4.3% (Ault Global Holdings: Ault & Company agrees to acquire 1 mln shares of its common stock)
- LEU +4.2% (US Nuclear Regulatory Commission approves license amendment request to produce HALEU)
- AXSM +3.3% (plan to submit a NDA for AXS-14 for the management of fibromyalgia following a pre-NDA meeting with the FDA)
- SAVE +2.8% (provides upbeat Q2 guidance and operational trends; leisure demand has continued to improve throughout Q2)
- BRP +2.5% (to acquire RogersGray)
- BDSX +2.5% (Biodesix SARS CoV-2 Neutralization Antibody Test now commercially available)
- CMRE +2.1% (acquires 16 dry bulk vessels)
- CLLS +1.9% (announces four new product candidates under pre-clinical development; also announces .HEAL, its genome surgery platform)
- HEAR +1.5% (enters two new market segments with Recon Controller and Velocityone Flight simulation control system)
- NVAX +1.5% (reports "positive results" from first study of influenza vaccine and COVID-19 vaccine candidate administrated at same time)
- IBRX +1.3% (receives authorization from FDA for study of Anktiva and PD-L1 t-haNK)
Analyst comments:
- FOA +6.2% (upgraded to Strong Buy from Outperform at Raymond James)
- LX +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- WELL +1.1% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- WPC +0.9% (upgraded to Overweight from Neutral at JP Morgan)